, with another 200,000 scheduled to arrive in the third quarter of 2022 and a news report indicates that the Imvanex vaccine has been administered in Portugal since July 16.(36,37) In the UK, the Coalition for EpidemicPreparednessInnovations has awarded the UK Medicines and Healthcare products Regulatory Agency and the UK Health Security Agency funding to advance research into tools for assessing current with a known or probable case of monkeypox • The Coalition for EpidemicPreparednessInnovations has awarded the UK Medicines and Healthcare products Regulatory Agency and the UK Health Security Agency funding to advance research into tools for assessing current and future vaccines against monkeypox • At a recent press conference, Dr. Theresa Tam responded to questions about whether governments are looking
. To that end, WHO and partners* established the Access to COVID-19 Tools Accelerator (ACT-Accelerator) in April 2020. Together with Gavi and the Coalition for EpidemicPreparednessInnovations, WHO co-leads COVAX, the vaccines pillar of the ACT-Accelerator, which aims to ensure that no countries are left behind in the rush to roll out vaccines.FOREWORD FROM THE DIRECTOR-GENERAL* ACT-Accelerator partners include: The Bill & Melinda Gates Foundation; the Coalition for EpidemicPreparednessInnovations; FIND; Gavi, the Vaccine Alliance; the Global Fund to Fight AIDS, Tuberculosis and Malaria; Unicef; Unitaid; the Wellcome Trust; the World Bank Group; the International Federation of Pharmaceutical Manufacturers and Associations; and the Developing Countries Vaccine Manufacturers Network.vii22 January
Page (National Institute for Biological Standards and Control, U nited Kingdom), Diogo Marques (Epiconcept), Gabrielle Breugelmans (Coalition for EpidemicPreparednessInnovations), Miwako Kobayashi (Centers for Disease Control and Prevention, CDC, United States), Mark Tenforde (CDC, United States), Jennifer Verani (CDC, United States), Richard Pebody (World Health Organization Regional Office
the U.S. Food and Drug Administration (FDA) and Coalition for EpidemicPreparednessInnovations (CEPI) case definitions, respectively, and were contrasted to background community transmission and circulating SARS-CoV-2 variants. A total of 3665 HCWs were enrolled (mean follow-up time: 18 months); 97 met the FDA definition of virologically confirmed COVID-19 (incidence rate (IR) 2.3/1000 person-months
administration for prophylactic vaccination in at-risk populations. Innovative Medicines Initiative 2 Joint Undertaking and Coalition for EpidemicPreparednessInnovations.
these findings in groups at risk for MERS-CoV exposure, and at risk of severe disease, including older individuals and those with relevant comorbidities. Coalition for EpidemicPreparednessInnovations, the German Centre for Infection Research, and the German Research Foundation.
that protected 10 of 10 vaccinated macaques from disease supporting its use in a clinical development program, which recently progressed to phase 2 clinical trials. Moreover, immunologic analysis showed that virus-neutralizing serum antibodies likely played a role in preventing LASV disease in vaccinated macaques. This work was supported by the Coalition for EpidemicPreparednessInnovations (CEPI
response and the generation of seroprotective titres in almost all vaccinated participants suggests that VLA1553 is an excellent candidate for the prevention of disease caused by chikungunya virus. Valneva, Coalition for EpidemicPreparednessInnovation, and EU Horizon 2020.
to be unaffected by pre-existing immunity against the vector. MV-LASV is therefore a promising candidate for further development. Coalition for EpidemicPreparednessInnovations.
events related to vaccination. VLA1553 is an efficient and safe intervention that offers high seroprotection against chikungunya virus infection, a virus likely to spread globally with an urgent demand for long-lasting prophylaxis. Valneva Austria, Coalition for EpidemicPreparednessInnovation, and EU Horizon 2020.
adolescents with favourable safety data in adolescents who were seropositive at baseline. The data support the use of VLA1553 for the prevention of disease caused by the chikungunya virus among adolescents and in endemic areas. Coalition for EpidemicPreparednessInnovation and EU Horizon 2020. For the Portuguese translation of the abstract see Supplementary Materials section.
that, in the absence of other risk factors, this group may in future be able to follow the general recommendations for COVID-19 vaccines. South-Eastern Norway Regional Health Authority, Coalition for EpidemicPreparednessInnovations (CEPI), Norwegian Institute of Public Health, Akershus University Hospital, Diakonhjemmet Hospital.
for designing future phase III vaccine trials in which infection is an outcome. UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for EpidemicPreparednessInnovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, AstraZeneca.
with the high-dose administration. The findings strongly support further clinical development of this candidate vaccine for human use. The Coalition for EpidemicPreparednessInnovations with support from the EU Horizon 2020 programme.
, these investments must be enhanced by prioritising a more equitable global vaccine distribution. Schmidt Science Fellowship in partnership with the Rhodes Trust, WHO, UK Medical Research Council, Coalition for EpidemicPreparednessInnovations.
with homologous schedules. Multiple vaccines are appropriate to complete primary immunisation following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification. UK Vaccine Task Force, Coalition for EpidemicPreparednessInnovations (CEPI), and National Institute for Health Research. NVX vaccine was supplied for use
provides notable protection against the entire severity spectrum of COVID-19 caused by circulating SAR-CoV-2 viruses, including the predominating delta variant. Clover Biopharmaceuticals and the Coalition for EpidemicPreparednessInnovations.
vaccine platforms deployed in the COVID-19 pandemic, suggest that heterologous priming schedules might be considered as a viable option sooner in future pandemics. 27841311 EudraCT:2021-001275-16 FUNDING: UK Vaccine Task Force (VTF), Coalition for EpidemicPreparednessInnovations (CEPI) and National Institute for Health and Carte Research (NIHR). NVX was supplied for trial use by Novavax, Inc.